IVF Add-Ons

IVF add-ons are the optional procedures, tests and technologies offered on top of standard treatment — embryo genetic screening (PGT-A), endometrial receptivity testing, endometrial scratching, immune therapies (intralipid infusions, IVIG, steroids), embryo glue, time-lapse incubation, assisted hatching, routine ICSI without male-factor indication — typically priced from hundreds to several thousand per item per cycle, on top of base costs that already strain most patients. Uptake is the market's tell: large majorities of private-clinic patients report using at least one add-on, the UK regulator's national survey found only 37% were told about risks before agreeing, and the sales context is structurally loaded — a failed cycle, a couple who will pay anything, and a clinic that profits from the upgrade. This hub applies the collection's marketplace doctrine to the industry where evidence-free premium pricing meets the most motivated buyers in medicine.

The UK's HFEA — the only national regulator that publicly rates add-ons — introduced its traffic-light system in 2019 and overhauled it into five categories in 2023, assessing the most commonly sold add-ons against randomised evidence for the outcome that matters: live birth. The standing verdict: not one of the thirteen reviewed add-ons meets the criteria for clear evidence of benefit for the general IVF population; ratings cluster in "insufficient evidence" and several sit at "may reduce effectiveness or raise safety concerns". Europe's professional body reached the same territory independently — the ESHRE 2023 good-practice recommendations assessed 42 interventions and advised against routine use for nearly all. The pattern to internalise: these are not exotic experimental therapies awaiting data; most have been sold for a decade-plus, several have now had large trials — and the trials keep coming back null.

Case files on the top sellers. PGT-A (embryo aneuploidy screening, often ~£/$3,000-6,000): the flagship STAR randomised trial found no overall live-birth improvement; plausible per-transfer benefit in older women trades against discarding potentially viable mosaic embryos and cumulative-outcome neutrality — defensible in selected cases, indefensible as the routine upsell it became. Endometrial scratching: the large PIP randomised trial — null; a practice performed on millions retired by evidence. ERA (endometrial receptivity testing, ~$1,000+): subsequent randomised testing found no live-birth benefit over standard timing. Time-lapse incubation: the 2024 multicentre randomised trial and Cochrane — no improvement over standard incubation; pleasant videos, premium price. Immune therapies (intralipid, IVIG, steroids for "natural killer cells"): biologically incoherent testing, no reproducible benefit, real costs and risks — the closest thing this market has to pure theatre. Embryo glue: marginal-to-null. Routine ICSI without male factor (now used in the majority of world cycles): no benefit over conventional IVF in non-male-factor couples per trials and ASRM/Cochrane — an add-on so normalised it stopped looking like one.

The add-on economy thrives on mechanisms this collection catalogues elsewhere, here in concentrated form. Desperation pricing: after two failed cycles, "is there anything else we can try" is not a question evidence answers — it is a question hope asks, and a menu answers. Plausibility theatre: every add-on has a mechanism story (screen the embryos, time the window, calm the immune system) that sounds like precision medicine and substitutes for outcome data. Per-transfer statistics: improving success per transfer while leaving success per patient unchanged — PGT-A's core sleight — reads as benefit to anyone not briefed on the difference. Defensive adoption: clinics stock add-ons because competitors do and patients ask; embryologists privately sceptical still sell the package. Asymmetric accountability: a baby after add-ons credits the add-on; a failure after declining one indicts the declining — heads the upsell wins, tails the patient blames herself. And regulatory vacuum: outside the UK's rating system, most of the world's clinics face no obligation even to disclose the evidence state, and the largest markets run on clinic websites as the information environment.

The honest hub separates racket from tool. Genuinely indicated uses exist: ICSI for actual male-factor infertility (its designed purpose, where it is transformative); PGT-M/PGT-SR for known genetic disease or translocations (different tests from routine PGT-A, with clear rationale); PGT-A within honest counselling for selected older patients prioritising per-transfer efficiency or miscarriage reduction over cumulative rates; frozen-embryo strategies and endometrial preparation choices grounded in real trial literature; and participation in actual registered trials of new techniques — the legitimate home for innovation, with add-ons as the illegitimate one. The reframe for patients: the evidence-supported levers in IVF are unglamorous and mostly free — the right clinic (success rates vary far more between clinics than between add-ons), the right protocol, single-embryo transfer strategy, weight/smoking/alcohol optimisation, and cycle count persistence — while the paid menu mostly sells control back to people the process has stripped it from.

Before any add-on, ask four questions and require answers in writing: What is the randomised evidence that this improves live birth for patients like me (age, diagnosis, history)? What does the UK HFEA rating and the ESHRE guidance say about it? What does it cost across my expected number of cycles? And would you offer it to your own family at this price? Then apply the defaults: decline routine PGT-A, ERA, scratching, immune infusions, embryo glue, time-lapse upgrades and non-indicated ICSI unless your specific situation matches the narrow defensible uses above — and treat any clinic that bristles at the questions as data about the clinic. Spend the saved money where variance actually lives: clinic choice (verified success rates for your age band), an extra cycle, or counselling support. Desperation is the product being monetised; the questions are the armour.